Exelixis, Inc.
EXEL
Rank in Stocks
#1410
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer,... Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.
Share Price
$62.61
Last synced: 2026-10-19
Market Cap
$15.74B
Change (1 day)
0.61%
Change (1 year)
81.28%
Country
US
Trade Exelixis, Inc. (EXEL)
Category
Healthcare
P/E ratio for Exelixis, Inc. (EXEL)
P/E ratio as of October 2026 TTM: 18.54
According to Exelixis, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 18.54. At the end of 2025 the company had a P/E ratio of 18.90.
P/E ratio history for Exelixis, Inc. from 2000 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 18.54 | -1.92% |
| 2025 | 18.90 | -48.55% |
| 2023 | 36.74 | 29.84% |
| 2022 | 28.29 | 13.57% |
| 2021 | 24.91 | 55.37% |
| 2020 | 16.03 | 91.06% |
| 2018 | 8.39 | -85.50% |
| 2017 | 57.87 | -208.79% |
| 2016 | -53.19 | 5,005.52% |
| 2014 | -1.04 | -77.39% |
| 2013 | -4.61 | -5.78% |
| 2012 | -4.89 | -162.05% |
| 2011 | 7.88 | -181.69% |
| 2010 | -9.65 | 185.36% |
| 2009 | -3.38 | -66.78% |
| 2007 | -10.18 | 32.57% |
| 2006 | -7.68 | -12.69% |
| 2005 | -8.80 | 75.26% |
| 2004 | -5.02 | 3.18% |
| 2003 | -4.86 | -7.50% |
| 2002 | -5.26 | -51.55% |
| 2001 | -10.85 | 80.10% |
| 2000 | -6.03 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 28.78 | 55.26% |
US
|
|
| -28.36 | -252.97% |
US
|
|
| -24.57 | -232.52% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | 63.61% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.